Gainers
- NewGenIvf Group NIVF stock increased by 112.2% to $3.65 during Tuesday's regular session. The market value of their outstanding shares is at $2.7 million.
- Reshape Lifesciences RSLS stock rose 53.82% to $6.63. The company's market cap stands at $4.8 million.
- Biomea Fusion BMEA shares rose 52.58% to $2.37. The company's market cap stands at $85.7 million.
- Traws Pharma TRAW stock moved upwards by 39.43% to $1.98. The market value of their outstanding shares is at $11.0 million.
- I-MAB IMAB shares moved upwards by 38.28% to $1.77. The market value of their outstanding shares is at $143.1 million.
- Perspective Therapeutics CATX stock moved upwards by 33.47% to $3.19. The company's market cap stands at $236.7 million.
Losers
- Ernexa Therapeutics ERNA shares fell 17.8% to $0.18 during Tuesday's regular session. The company's market cap stands at $11.2 million.
- Intensity Therapeutics INTS shares decreased by 15.87% to $0.5. The company's market cap stands at $9.1 million.
- Kairos Pharma KAPA shares fell 15.83% to $0.5. The company's market cap stands at $8.3 million.
- Zhengye Biotechnology ZYBT stock declined by 14.52% to $7.83. The company's market cap stands at $371.0 million.
- Clene CLNN shares fell 12.86% to $4.27. The company's market cap stands at $38.3 million.
- Akoya Biosciences AKYA stock decreased by 12.0% to $1.1. The company's market cap stands at $54.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
BMEABiomea Fusion Inc
$1.901.06%
Edge Rankings
Momentum
4.71
Price Trend
Short
Medium
Long
CATXPerspective Therapeutics Inc
Not Available-%
CLNNClene Inc
$3.50-10.1%
ERNAErnexa Therapeutics Inc
$1.95-4.36%
IMABI-MAB
$2.11-2.31%
INTSIntensity Therapeutics Inc
$0.3289-1.38%
KAPAKairos Pharma Ltd
$1.096.86%
NIVFNewGenIvf Group Ltd
$0.5700-6.25%
RSLSReshape Lifesciences Inc
$3.1510.5%
TRAWTraws Pharma Inc
$1.684.00%
ZYBTZhengye Biotechnology Holding Ltd
$5.70-2.90%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.